For anyone living with Endometriosis, the words “new treatment” can bring an enormous amount of hope.

But our community has also learned to ask questions.

What has actually been proven?
Has it been tested in humans?
Is it hormonal?
Could it treat the disease itself rather than only helping manage symptoms?
And when could something like this actually become available?

Those questions are particularly important when discussing ENDO-205, an investigational treatment currently being developed by EndoCyclic Therapeutics.

In March 2026, ENDO-205 reached an important milestone when the U.S. Food and Drug Administration cleared its Investigational New Drug application, allowing the program to progress into human clinical development. 

It is an exciting development.

But FDA clearance of an IND is not the same as FDA approval of a treatment, and ENDO-205 has not yet been proven to treat Endometriosis in humans.

So, what exactly is ENDO-205, and why is this research attracting attention?

First, why do we need different Endometriosis treatments?

Endometriosis is a chronic disease characterised by tissue similar to the lining of the uterus growing elsewhere in the body. Although it most commonly occurs within the pelvis, Endometriosis can occur outside the pelvis as well. It can cause inflammation, pain, fertility difficulties and symptoms involving areas such as the bowel and bladder. 

For many Warriors, treatment becomes a long-term process rather than a simple solution.

Current treatment in Australia can include pain-relieving medicines, hormonal medications, surgery, pelvic floor physiotherapy, psychological support and multidisciplinary pain management. Hormonal options include medications such as oral contraceptives, progestogens and GnRH therapies. 

These treatments can be incredibly important and beneficial for some people.

But they don’t work for everybody.

Hormonal treatment may not be appropriate or tolerable for everyone, surgery carries its own considerations, and symptoms can persist or recur. There is currently no known cure for Endometriosis. 

That is part of what makes research into genuinely different therapeutic approaches so important.

So, what is ENDO-205?

ENDO-205 is an investigational, non-hormonal peptide therapeutic being developed specifically for Endometriosis.

Its developer, EndoCyclic Therapeutics, describes its technology as a targeted peptide platform in which peptides are selectively absorbed by diseased tissue and interact with intracellular targets. The goal is to target disease biology while limiting effects on surrounding healthy tissue. 

NIH-funded project information provides more detail.

According to NIH RePORTER, ENDO-205 was developed to target a downstream component of a pathway involved in Endometriosis pathogenesis, migration and invasion. The project describes selective absorption into Endometriosis tissue and a non-hormonal mechanism. 

That’s a fundamentally interesting distinction.

Instead of suppressing ovarian hormones, researchers are investigating whether they can selectively target biological processes associated with the Endometriosis tissue itself.

Why does “non-hormonal” matter?

Hormonal treatments remain an important part of Endometriosis care, and this research should not be interpreted as evidence that hormonal treatments are ineffective or inappropriate.

But a non-hormonal treatment could potentially provide another option for people for whom hormonal suppression is unsuitable, poorly tolerated or simply not what they want.

ENDO-205 is being developed without relying on ovarian hormone suppression.

In the preclinical research described by NIH, ENDO-205 was associated with lesion regression and disappearance without altering the reproductive cycle in the animal models studied. 

That combination is one reason this research has attracted attention.

But there is a very important word in that sentence: Preclinical.

What has the research actually shown?mThis is where we need to separate excitement from evidence.

Research described by EndoCyclic and NIH reports promising preclinical findings involving Endometriosis lesions. NIH documentation reports lesion regression and disappearance in the preclinical program and says earlier development generated efficacy and toxicology data supporting progression of the program. 

Those findings helped researchers move towards the next stage of development.

However, results in laboratory and animal research cannot tell us that the same outcome will occur in humans.

We do not yet know whether ENDO-205 will eliminate lesions in people.

We do not yet know whether it will reduce Endometriosis pain.

We do not yet know what side effects could emerge in humans.

We do not yet know how long any benefit might last.

And we certainly cannot call ENDO-205 a cure.

The researchers themselves have described the development goal using terms including “disease-modifying” and “curative”, but these describe the goal of the investigational program, not an established clinical outcome. 

That distinction matters enormously.

What happened in March 2026?

This is probably the biggest development people need to understand.

On March 23rd, 2026, EndoCyclic Therapeutics announced that the U.S. FDA had cleared its Investigational New Drug (IND) application for ENDO-205. 

An IND allows an investigational drug development program to move into human clinical testing in the United States.

It does not mean:

ENDO-205 has been approved as an Endometriosis treatment.

It does not mean:

Researchers have proven that it works in people.

And it does not mean:

Your doctor in the USa can prescribe ENDO-205.

What it does mean is that ENDO-205 has crossed an important regulatory threshold on the pathway towards human clinical research.

That is significant.

What happens when human trials begin?

Early human research is primarily about answering foundational questions.

Is the drug tolerated?

What happens to it inside the body?

What dose should researchers investigate?

Are there safety concerns?

Those questions have to come before researchers can establish whether a treatment actually improves Endometriosis outcomes.

For our community, this is an important reminder that clinical development is a process.

One encouraging milestone does not automatically become an available treatment.

What do we still need to learn?

A lot.

And that isn’t pessimism. It’s science.

Among the biggest questions are:

Safety: What adverse effects or tolerability issues appear when ENDO-205 is administered to humans?

Effectiveness: Does it actually reduce Endometriosis lesions in people?

Pain: If lesions change, does that translate into meaningful improvements in pain and quality of life?

Durability: If it works, how long do the effects last?

Recurrence: Could lesions return following treatment?

Fertility: What impact, if any, could treatment have on fertility and reproductive outcomes?

Different forms of disease: Would the treatment perform similarly across superficial, ovarian, deep or extrapelvic disease?

Eligibility: Who might eventually qualify for treatment?

Accessibility: If ultimately approved, how much would it cost and who would be able to access it?

These are questions that clinical research will need to answer.

Is ENDO-205 available in Australia?

At this stage, ENDO-205 should not be considered an available Australian Endometriosis treatment.

The regulatory milestone announced in March relates to the U.S. FDA and the American clinical-development pathway. 

Australian access would involve separate clinical and regulatory processes.

So if you see social-media posts suggesting that ENDO-205 is already an available “new cure” for Endometriosis, approach those claims carefully.

That isn’t where the science currently stands.

Why are we talking about it so early?

Because our community shouldn’t have to wait until a medication appears on a pharmacy shelf before being included in conversations about Endometriosis research.

We can learn about emerging science while still being responsible about its limitations.

We can be excited about researchers investigating disease-targeted, non-hormonal therapies while acknowledging that they might not ultimately succeed.

We can celebrate progress without promising an outcome.

And perhaps most importantly, Warriors deserve the information necessary to understand the difference between a promising laboratory finding, an investigational medicine, a clinical trial and an approved treatment.

Those distinctions protect our community from misinformation without taking away something equally important:

Hope.

Hope matters. So does evidence.

ENDO-205 isn’t a proven treatment.

It isn’t an approved treatment.

And right now, nobody can tell us whether it will ultimately become part of Endometriosis care.

But it represents something our community has been asking for for a very long time: researchers investigating new ways of approaching the disease beyond the treatment options we already have.

For a community accustomed to hearing the same options discussed again and again, that is worth following.

Not because we know how this story ends.

But because research has to begin somewhere.

At The Endo Essentials, we’ll continue following ENDO-205 as the research progresses, breaking down the science in language our community can actually understand and clearly separating what researchers hope a treatment will do from what the evidence has actually proven.

Because Warriors deserve both.

Hope for a brighter tomorrow, and accurate information about how we get there. 💛

This article is provided for educational purposes only and does not constitute medical advice. ENDO-205 is an investigational therapeutic and has not been established as a safe or effective treatment for Endometriosis. Research and regulatory status can change. Speak with your healthcare professional about your individual treatment options.

Further reading:

• EndoCyclic Therapeutics⁠
• NIH RePORTER ENDO-205 project⁠
• Healthdirect Australia: Endometriosis⁠